Nearly 24% of patients with advanced CKD, including those on dialysis, have gout, according to a study.
In a study of patients with stage 4 chronic kidney disease and poorly controlled blood pressure, chlorthalidone significantly decreased systolic blood pressure compared with placebo.
Each 1 mg/dL rise in uric acid level was significantly associated with a 21% and 10% increased risk for cardiovascular and all-cause mortality, respectively, a study found.
Visceral fat area was significantly associated with the risk for cardiovascular events and death and all-cause mortality, whereas coronary artery calcification score was not, a study found.
In a clinical trial, renal denervation was associated with decreased plasma renin activity and aldosterone levels compared with a sham procedure.
Severe renal arteriosclerosis in diagnostic lupus nephritis biopsies is associated with 9-fold higher odds of atherosclerotic cardiovascular disease.
In the BETonMACE trial, CKD patients with type 2 diabetes who recently experienced acute coronary syndrome who received apabetalone had a significant 50% reduction in the risk for major cardiovascular events compared with placebo.
Patients with heart failure who remained on mineralocorticoid receptor antagonists after a hyperkalemia episode had a lower risk for major cardiovascular events than those who stopped taking the medications, a study found.
